Lavin P J, Laing M E, O'Kelly P, Moloney F J, Gopinathan D, Aradi A Al, Shields D C, Murphy G M, Conlon P J
Department of Nephrology, Beaumont Hospital, Dublin 9, Ireland.
Ren Fail. 2007;29(7):785-9. doi: 10.1080/08860220701540417.
Polymorphisms in genes, coding for proteins involved in immune response, or the pathogenesis of atherosclerosis may influence immunological and non-immunological mechanisms that lead to allograft loss. Vitamin D receptor (VDR) agonists reduce allograft rejection in animal models, and there are a number of functional polymorphisms in VDR.
In all, 379 renal transplant recipients were genotyped for VDR (FokI & ApaI) polymorphisms, and the association of each genotype with renal allograft survival and acute rejection was determined.
There was significantly improved allograft survival for patients who were homozygous or heterozygous for the VDR FokI T allele (Hazard Ratio [HR] = 0.488, p < 0.001).
The association of VDR FokI T allele with improved renal allograft survival is a unique observation. The finding is in keeping with data showing the prevention of chronic allograft rejection with the use of Vitamin D receptor agonists.
参与免疫反应或动脉粥样硬化发病机制的蛋白质编码基因中的多态性，可能会影响导致同种异体移植失败的免疫和非免疫机制。维生素D受体（VDR）激动剂可减少动物模型中的同种异体移植排斥反应，并且VDR存在许多功能性多态性。
总共对379名肾移植受者进行了VDR（FokI和ApaI）多态性基因分型，并确定了每种基因型与肾移植存活和急性排斥反应的关联。
VDR FokI T等位基因纯合或杂合的患者，其移植肾存活情况有显著改善（风险比[HR]=0.488，p<0.001）。
VDR FokI T等位基因与移植肾存活改善之间的关联是一项独特的观察结果。这一发现与使用维生素D受体激动剂预防慢性同种异体移植排斥反应的数据一致。
